Skip to main content
Signal8

CHAMPIONS ONCOLOGY, INC. (CSBR)

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Champions Oncology, Inc. logo

Champions Oncology, Inc.

NASDAQ:CSBRHealthcare
+0.00%$4.81
AH$4.81+0.00%vs close
Mkt Cap$66.95M
Float6.83M
O/S13.92M
Vol
$ Vol
RVOL
Inst Own42.2%
SI1.1%
Earnings
Dilution
Pipeline1 lead-sponsored trial·0 active0 completed(2 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
  • Not applicable
    Terminated

    Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

    PDX drug sensitivity testing

    Sarcoma

    Enrollment
    17
    Start
    Nov 2015
    Primary Completion
    Nov 2017est.
    Completion
    Nov 2017est.
    NCT02720796